Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Linde, Bayer deals in review

by Alex Scott
February 12, 2018 | A version of this story appeared in Volume 96, Issue 7

The European Commission has informed Linde and Bayer that their respective acquisitions of Praxair and Monsanto can go ahead only if they agree to divest chunks of their businesses postacquisition. Linde says European requirements to acquire Praxair will now be “more onerous than previously assumed.” Linde says it faces a second, more in-depth investigation into the impact of its planned deal on the competitiveness of Europe’s industrial gas sector. It’s set to conclude by May 7. Linde announced its deal to combine with Praxair in December 2016. Meanwhile, Bayer has offered to sell more businesses in order to satisfy European regulators reviewing its planned acquisition of Monsanto. The commission will decide by April 5 whether Bayer is offering enough. Bayer had already agreed to divest its glufosinate herbicide and glufosinate-resistant seeds businesses to BASF for $7 billion. Bayer’s deal to acquire Monsanto, announced in September 2016, will create a pesticides and seeds behemoth.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.